Qiangqiang Zhao1,2, Duanfeng Jiang3, Xiaoying Sun4,5, Qiuyu Mo6, Shaobin Chen2, Wansong Chen7, Rong Gui8, Xianjun Ma9. 1. Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. 2. Department of Hematology, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China. 3. Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. 4. Nursing School, Soochow University, Suzhou, 215000, People's Republic of China. 5. Department of Emergency, The Qinghai Provincial People's Hospital, Xining, 810007, People's Republic of China. 6. Department of Hematology, Affiliated Hospital of Guilin Medical University, Guilin, 541002, People's Republic of China. 7. College of Chemistry and Chemical Engineering, Central South University, Changsha, 410083, People's Republic of China. 8. Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. zndxgr@163.com. 9. Department of Blood Transfusion, Qilu Hospital of Shandong University, Jinan, 250012, People's Republic of China. 18560087567@163.com.
Abstract
BACKGROUND: Non-Hodgkin's lymphoma (NHL) is a malignant disease of lymphoid tissue. At present, chemotherapy is still the main method for the treatment of NHL. R-CHOP can significantly improve the survival rate of patients. Unfortunately, DOX is the main cytotoxic drug in R-CHOP and it can lead to adverse reactions. Therefore, it is particularly important to uncover new treatment options for NHL. RESULTS: In this study, a novel anti-tumor nanoparticle complex Nm@MSNs-DOX/SM was designed and constructed in this study. Mesoporous silica nanoparticles (MSNs) loaded with Doxorubicin (DOX) and anti-inflammatory drugs Shanzhiside methylester (SM) were used as the core of nanoparticles. Neutrophil membrane (Nm) can be coated with multiple nanonuclei as a shell. DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-α and IL-1β. Consequently, the tumor microenvironment (TME) was reshaped, and the anti-tumor effect of DOX was amplified. Besides, Nm has good biocompatibility and can enhance the EPR effect of Nm@MSNs-DOX/SM and increase the effect of active targeting tumors. CONCLUSIONS: This suggests that the Nm-modified drug delivery system Nm@MSNs-DOX/SM is a promising targeted chemotherapy and anti-inflammatory therapy nanocomplex, and may be employed as a specific and efficient anti-Lymphoma therapy.
BACKGROUND:Non-Hodgkin's lymphoma (NHL) is a malignant disease of lymphoid tissue. At present, chemotherapy is still the main method for the treatment of NHL. R-CHOP can significantly improve the survival rate of patients. Unfortunately, DOX is the main cytotoxic drug in R-CHOP and it can lead to adverse reactions. Therefore, it is particularly important to uncover new treatment options for NHL. RESULTS: In this study, a novel anti-tumor nanoparticle complex Nm@MSNs-DOX/SM was designed and constructed in this study. Mesoporous silica nanoparticles (MSNs) loaded with Doxorubicin (DOX) and anti-inflammatory drugs Shanzhiside methylester (SM) were used as the core of nanoparticles. Neutrophil membrane (Nm) can be coated with multiple nanonuclei as a shell. DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-α and IL-1β. Consequently, the tumor microenvironment (TME) was reshaped, and the anti-tumor effect of DOX was amplified. Besides, Nm has good biocompatibility and can enhance the EPR effect of Nm@MSNs-DOX/SM and increase the effect of active targeting tumors. CONCLUSIONS: This suggests that the Nm-modified drug delivery system Nm@MSNs-DOX/SM is a promising targeted chemotherapy and anti-inflammatory therapy nanocomplex, and may be employed as a specific and efficient anti-Lymphoma therapy.
Authors: S Karthik; Nagaprasad Puvvada; B N Prashanth Kumar; Shashi Rajput; Amita Pathak; Mahitosh Mandal; N D Pradeep Singh Journal: ACS Appl Mater Interfaces Date: 2013-06-03 Impact factor: 9.229
Authors: Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani Journal: N Engl J Med Date: 2020-02-06 Impact factor: 91.245
Authors: Ramin Hassankhani; Mohammad Esmaeillou; Ali Asghar Tehrani; Keyvan Nasirzadeh; Fatemeh Khadir; Hamid Maadi Journal: Environ Sci Pollut Res Int Date: 2014-08-13 Impact factor: 4.223
Authors: Cristina Carvalho; Renato X Santos; Susana Cardoso; Sónia Correia; Paulo J Oliveira; Maria S Santos; Paula I Moreira Journal: Curr Med Chem Date: 2009-09-01 Impact factor: 4.530